Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Arch names Dr. Patrick Vink as chairman of BOD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026. Dr. Vink, MD, MBA, has been an advisor to...

January 16, 2026

Developments

Profusa initiates first commercial revenue with healthcare research offerings launch

Profusa (NASDAQ: PFSA) has announced the launch of its healthcare research version of its Lumee tissue oxygen monitoring into the contract research organizations (CRO) market, which is expected to generate immediate...

January 16, 2026

Developments

GT submits IND for GTB-5550 TriKE in solid tumors

GT Biopharma (NASDAQ: GTBP) has announced that it submitted an investigational new drug (IND) application to the FDA in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the...

January 15, 2026

Developments

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model...

January 15, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Developments

cbdMD acquires Bluebird Botanicals

cbdMD (NYSE American: YCBD) has announced the strategic acquisition of closely held Bluebird Botanicals through an asset purchase comprised of an initial share issuance and earnout shares. According to cbdMD, the...

January 14, 2026

Developments

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the...

January 14, 2026

Executive Moves

Oncolytics names John McAdory EVP strategy and operations; Yujun Wu VP biostatistics

Oncolytics Biotech (NASDAQ: ONCY) has announced the appointments of John McAdory as executive vice president (EVP), strategy and operations, and Yujun Wu as vice president (VP), head of biostatistics. According to...

January 14, 2026

Developments

Profound surpasses 2025 TULSA-PRO installed base goal

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025. The company’s TULSA...

January 12, 2026

Developments

Nature Eye publishes positive Phase 1 results for Ocugen’s gene therapy

Ocugen (NASDAQ: OCGN) has announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye, published by...

January 12, 2026

Executive Moves

Achieve appoints Dr. Mark Rubenstein as CMO

Achieve Life Sciences (NASDAQ: ACHV) has announced the promotion of Mark Rubenstein, MD, from interim chief medical officer (CMO) to CMO. Dr. Rubinstein brings more than two decades of experience in clinical medicine...

January 12, 2026

Developments

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74%...

January 9, 2026

Subscribe